Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1, single- center, open- label, fixed- sequence, drug- drug interaction study assessing the effect of multiple doses of a strong CYP3A4 and P-gp inhibitor (itraconazole) on the single- dose pharmacokinetics of intranasal and oral Zavegepant in healthy adults

Next Previous
Trial Profile

A phase 1, single- center, open- label, fixed- sequence, drug- drug interaction study assessing the effect of multiple doses of a strong CYP3A4 and P-gp inhibitor (itraconazole) on the single- dose pharmacokinetics of intranasal and oral Zavegepant in healthy adults

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 14 Jun 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zavegepant (Primary) ; Zavegepant (Primary) ; Itraconazole
  • Indications Allergic asthma; COVID-19 respiratory infection; Migraine
  • Focus Pharmacokinetics

Most Recent Events

  • 27 Apr 2023 Results assessing the multiple-dose itraconazole, a strong cytochrome (CYP)3A4 and P-glycoprotein (P-gp) inhibitor, on single-dose zavegepant (oral and nasal spray) pharmacokinetics (PK) in healthy adults and assess safety and tolerability, presented at the 75th Annual Meeting of the American Academy of Neurology 2023.
  • 04 Aug 2022 New trial record
  • 12 Jun 2022 Results presented at the 64th Annual Scientific Meeting of the American Headache Society

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top